PL2473507T3 - Trwałe kompozycje SNS-595 i sposoby ich wytwarzania - Google Patents

Trwałe kompozycje SNS-595 i sposoby ich wytwarzania

Info

Publication number: PL2473507T3
Authority: PL; Poland
Prior art keywords: compositions; preparation; methods; sns; stable
Prior art date: 2009-09-04

Application number

PL10759761T

Other languages

English (en)

Inventor

Anantha Sudhakar

Jeff Jacobs

Ahmad Hashash

Sean Ritchie

Hengqin Cheng

Original Assignee

Sunesis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-04

Filing date

2010-09-03

Publication date

2014-08-29

2010-09-03 Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc

2014-08-29 Publication of PL2473507T3 publication Critical patent/PL2473507T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Compounds Of Unknown Constitution (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Compositions Of Macromolecular Compounds (AREA)

PL10759761T 2009-09-04 2010-09-03 Trwałe kompozycje SNS-595 i sposoby ich wytwarzania PL2473507T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US24016109P	2009-09-04	2009-09-04
PCT/US2010/047776 WO2011028979A1 (en)	2009-09-04	2010-09-03	Stable sns-595 compositions and methods of preparation
EP10759761.9A EP2473507B1 (en)	2009-09-04	2010-09-03	Stable sns-595 compositions and methods of preparation

Publications (1)

Publication Number	Publication Date
PL2473507T3 true PL2473507T3 (pl)	2014-08-29

Family

ID=42990341

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10759761T PL2473507T3 (pl)	2009-09-04	2010-09-03	Trwałe kompozycje SNS-595 i sposoby ich wytwarzania

Country Status (25)

Country	Link
US (5)	US8586601B2 (pl)
EP (2)	EP2674431A1 (pl)
JP (3)	JP6339315B2 (pl)
KR (3)	KR101811763B1 (pl)
CN (2)	CN104177359B (pl)
AU (1)	AU2010289337B2 (pl)
BR (1)	BR112012004916A2 (pl)
CA (2)	CA2772291A1 (pl)
CL (1)	CL2012000565A1 (pl)
CO (1)	CO6511211A2 (pl)
DK (1)	DK2473507T3 (pl)
EA (2)	EA201400683A1 (pl)
ES (1)	ES2462502T3 (pl)
HR (1)	HRP20140372T1 (pl)
IL (3)	IL218404A (pl)
MX (1)	MX2012002573A (pl)
NZ (2)	NZ623780A (pl)
PH (1)	PH12014500714B1 (pl)
PL (1)	PL2473507T3 (pl)
PT (1)	PT2473507E (pl)
SG (3)	SG2014013163A (pl)
TW (2)	TWI615391B (pl)
UA (1)	UA110465C2 (pl)
WO (1)	WO2011028979A1 (pl)
ZA (1)	ZA201201469B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2559652C (en)	2004-03-15	2017-02-14	Sunesis Pharmaceuticals, Inc.	Methods of using sns-595 in treating cancer
US20100048609A1 (en) *	2006-08-01	2010-02-25	Jacobs Jeffrey W	Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP2214662B1 (en)	2007-10-22	2016-07-13	Sunesis Pharmaceuticals, Inc.	(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2249831A2 (en)	2007-12-10	2010-11-17	Sunesis Pharmaceuticals, Inc.	Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko)	2008-12-31	2017-08-07	선에시스 파마슈티컬스 인코포레이티드	(＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
UA110465C2 (en)	2009-09-04	2016-01-12	Sunesis Pharmaceutecals Inc	Stable sns-595 composition
BR112021024310A2 (pt)	2019-06-05	2022-02-15	Univ Emory	Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6233176A (ja) *	1985-08-05	1987-02-13	Toyama Chem Co Ltd	１，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
DK0787726T3 (da)	1994-06-14	2002-02-11	Dainippon Pharmaceutical Co	Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel
JPH10173986A (ja)	1996-12-16	1998-06-26	Sony Corp	移動体撮影装置
JP4294121B2 (ja)	1998-06-05	2009-07-08	大日本住友製薬株式会社	ピリドンカルボン酸誘導体の製造方法およびその中間体
JP4178783B2 (ja)	2001-10-19	2008-11-12	三菱化学株式会社	光学記録媒体
CA2559652C (en)	2004-03-15	2017-02-14	Sunesis Pharmaceuticals, Inc.	Methods of using sns-595 in treating cancer
US8580814B2 (en)	2006-04-03	2013-11-12	Sunesis Pharmaceuticals, Inc.	Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2007258280B2 (en)	2006-06-12	2013-05-02	Sunesis Pharmaceuticals, Inc.	Compounds and compositions for treatment of cancer
US20100048609A1 (en)	2006-08-01	2010-02-25	Jacobs Jeffrey W	Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DK2049109T3 (en)	2006-08-02	2016-01-11	Sunesis Pharmaceuticals Inc	Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
EP2214662B1 (en)	2007-10-22	2016-07-13	Sunesis Pharmaceuticals, Inc.	(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2249831A2 (en)	2007-12-10	2010-11-17	Sunesis Pharmaceuticals, Inc.	Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko) *	2008-12-31	2017-08-07	선에시스 파마슈티컬스 인코포레이티드	(＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
WO2010099526A1 (en)	2009-02-27	2010-09-02	Sunesis Pharmaceuticals, Inc.	Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en)	2009-09-04	2016-01-12	Sunesis Pharmaceutecals Inc	Stable sns-595 composition
TW201120037A (en)	2009-10-26	2011-06-16	Sunesis Pharmaceuticals Inc	Compounds and methods for treatment of cancer

2010
- 2010-03-09 UA UAA201204145A patent/UA110465C2/uk unknown
- 2010-09-03 CA CA2772291A patent/CA2772291A1/en not_active Abandoned
- 2010-09-03 HR HRP20140372AT patent/HRP20140372T1/hr unknown
- 2010-09-03 MX MX2012002573A patent/MX2012002573A/es unknown
- 2010-09-03 NZ NZ623780A patent/NZ623780A/en not_active IP Right Cessation
- 2010-09-03 PL PL10759761T patent/PL2473507T3/pl unknown
- 2010-09-03 ES ES10759761.9T patent/ES2462502T3/es active Active
- 2010-09-03 CA CA3002440A patent/CA3002440A1/en not_active Abandoned
- 2010-09-03 AU AU2010289337A patent/AU2010289337B2/en not_active Ceased
- 2010-09-03 US US12/875,927 patent/US8586601B2/en not_active Expired - Fee Related
- 2010-09-03 TW TW099129946A patent/TWI615391B/zh not_active IP Right Cessation
- 2010-09-03 SG SG2014013163A patent/SG2014013163A/en unknown
- 2010-09-03 EA EA201400683A patent/EA201400683A1/ru unknown
- 2010-09-03 EA EA201270377A patent/EA201270377A1/ru unknown
- 2010-09-03 WO PCT/US2010/047776 patent/WO2011028979A1/en not_active Ceased
- 2010-09-03 NZ NZ598467A patent/NZ598467A/en not_active IP Right Cessation
- 2010-09-03 BR BR112012004916A patent/BR112012004916A2/pt not_active Application Discontinuation
- 2010-09-03 KR KR1020127008282A patent/KR101811763B1/ko not_active Expired - Fee Related
- 2010-09-03 PT PT107597619T patent/PT2473507E/pt unknown
- 2010-09-03 JP JP2012528076A patent/JP6339315B2/ja not_active Expired - Fee Related
- 2010-09-03 TW TW103137080A patent/TWI519535B/zh not_active IP Right Cessation
- 2010-09-03 KR KR1020177024177A patent/KR20170102568A/ko not_active Ceased
- 2010-09-03 CN CN201410318200.1A patent/CN104177359B/zh not_active Expired - Fee Related
- 2010-09-03 CN CN201080050160.7A patent/CN102596948B/zh not_active Expired - Fee Related
- 2010-09-03 EP EP13184180.1A patent/EP2674431A1/en not_active Withdrawn
- 2010-09-03 SG SG2012014866A patent/SG178956A1/en unknown
- 2010-09-03 KR KR1020187028458A patent/KR20180112103A/ko not_active Ceased
- 2010-09-03 SG SG10201808097QA patent/SG10201808097QA/en unknown
- 2010-09-03 DK DK10759761.9T patent/DK2473507T3/da active
- 2010-09-03 EP EP10759761.9A patent/EP2473507B1/en active Active
- 2010-12-30 US US12/982,785 patent/US8138202B2/en not_active Expired - Fee Related
2012
- 2012-02-28 ZA ZA2012/01469A patent/ZA201201469B/en unknown
- 2012-02-29 IL IL218404A patent/IL218404A/en not_active IP Right Cessation
- 2012-03-02 CL CL2012000565A patent/CL2012000565A1/es unknown
- 2012-03-05 CO CO12038188A patent/CO6511211A2/es unknown
2013
- 2013-10-16 US US14/055,590 patent/US9469635B2/en not_active Expired - Fee Related
2014
- 2014-03-28 PH PH12014500714A patent/PH12014500714B1/en unknown
2015
- 2015-03-12 IL IL237724A patent/IL237724A/en not_active IP Right Cessation
- 2015-12-18 JP JP2015247670A patent/JP2016104769A/ja active Pending
2016
- 2016-09-16 US US15/267,911 patent/US9969730B2/en active Active
- 2016-09-20 IL IL247929A patent/IL247929B/en not_active IP Right Cessation
2018
- 2018-03-05 JP JP2018038783A patent/JP2018127457A/ja active Pending
- 2018-04-11 US US15/951,061 patent/US20190084978A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ598467A (en)	2014-04-30
EP2674431A1 (en)	2013-12-18
CA3002440A1 (en)	2011-03-10
PT2473507E (pt)	2014-05-23
ZA201201469B (en)	2013-05-29
KR20170102568A (ko)	2017-09-11
US8586601B2 (en)	2013-11-19
KR101811763B1 (ko)	2017-12-22
HK1172032A1 (en)	2013-04-12
PH12014500714B1 (en)	2017-11-08
US8138202B2 (en)	2012-03-20
US9469635B2 (en)	2016-10-18
DK2473507T3 (da)	2014-04-22
TW201114767A (en)	2011-05-01
TW201504240A (zh)	2015-02-01
IL247929B (en)	2018-01-31
BR112012004916A2 (pt)	2017-07-04
JP6339315B2 (ja)	2018-06-06
CN104177359A (zh)	2014-12-03
IL218404A0 (en)	2012-04-30
CO6511211A2 (es)	2012-08-31
US20170226104A1 (en)	2017-08-10
CN102596948B (zh)	2015-07-22
NZ623780A (en)	2015-10-30
SG2014013163A (en)	2014-09-26
US20190084978A1 (en)	2019-03-21
AU2010289337A1 (en)	2012-03-22
US20110086876A1 (en)	2011-04-14
US9969730B2 (en)	2018-05-15
SG178956A1 (en)	2012-04-27
JP2018127457A (ja)	2018-08-16
PH12014500714A1 (en)	2015-09-07
EA201400683A1 (ru)	2015-05-29
KR20180112103A (ko)	2018-10-11
IL237724A (en)	2016-10-31
CN102596948A (zh)	2012-07-18
MX2012002573A (es)	2012-04-10
SG10201808097QA (en)	2018-10-30
US20110082169A1 (en)	2011-04-07
EA201270377A1 (ru)	2013-01-30
JP2016104769A (ja)	2016-06-09
ES2462502T3 (es)	2014-05-23
UA110465C2 (en)	2016-01-12
IL218404A (en)	2015-07-30
US20140275547A1 (en)	2014-09-18
HRP20140372T1 (hr)	2014-06-20
WO2011028979A1 (en)	2011-03-10
CL2012000565A1 (es)	2012-12-07
CN104177359B (zh)	2018-06-01
KR20120078711A (ko)	2012-07-10
AU2010289337B2 (en)	2014-10-30
EP2473507B1 (en)	2014-03-19
EP2473507A1 (en)	2012-07-11
CA2772291A1 (en)	2011-03-10
TWI615391B (zh)	2018-02-21
TWI519535B (zh)	2016-02-01
JP2013503899A (ja)	2013-02-04

Publication	Publication Date	Title
IL217280A0 (en)	2012-02-29	Compositions comprising combinations of phyto-cannabinoids and uses thereof
SG10201605794PA (en)	2016-09-29	Stable Pharmaceutical Composition And Methods Of Using Same
IL241098A0 (en)	2015-11-30	Antimicrobial preparations and methods of using them
IL214806A0 (en)	2011-11-30	Prebiotic formulations and methods of use
IL222291A0 (en)	2012-12-31	Compositions and methods of synthesis of pyridinoylpiperidine
ZA201208265B (en)	2013-07-31	Pharmaceutical compositions and methods of making same
EP2593571A4 (en)	2015-09-30	SWEETENER COMPOSITIONS AND METHODS OF PRODUCING THE SAME
EP2231665A4 (en)	2012-04-25	NEW COMPOSITIONS AND METHODS OF USE
IL247929B (en)	2018-01-31	Stable compositions of 595–sns and methods for their preparation
IL201364A0 (en)	2010-06-30	Gas-effusing compositions and methods of making and using same
EP2622029A4 (en)	2014-06-04	PRINTING COLORING COMPOSITIONS AND METHOD FOR THEIR USE
GB0812890D0 (en)	2008-08-20	Compositions and methods of making compositions
EP2566485A4 (en)	2014-03-12	IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF
PL2498613T3 (pl)	2015-08-31	Kompozycje biobójcze i sposoby ich stosowania
EP2381950A4 (en)	2012-08-22	COMPOSITIONS AND METHOD FOR THEIR USE
EP2411022A4 (en)	2012-10-17	COMPOSITIONS FOR A PROMPARATE AND METHOD FOR THEIR USE
GB201002278D0 (en)	2010-03-31	composition and method of preparation
AU2009905930A0 (en)	2009-12-24	Methods and Preparation and Uses of Xanthorrhoeaceae Compositions
AU2010905320A0 (en)	2010-12-23	Methods and Preparation and Uses of Xanthorrhoeaceae Compositions